CellMeat raises $13.34m in Series A round

Business

CellMeat raises $13.34m in Series A round

Phoebe Fraser

9 June 2023

CellMeat raises $13.34m in Series A round

South Korea-based cultivated seafood company CellMeat has raised KRW 17.4 billion (approx. $13.34 million) in a funding round.

The Series A was led by previous investors BNK Venture Investment, Ryukyung PSG Asset Management, and Strong Ventures, with three new investors – NH Venture Investment, Genting Ventures and Daewoodang Healthcare – also joining the round.

The announcement comes as CellMeat prepares to open a mass production centre in Guri, in South Korea’s Gyeonggi province, this month, after claiming to develop proprietary cell culture technology that makes large-scale production of cell-based meat economically viable.

CellMeat’s CEO, Park Gil-jun, said: “Through this Series A investment, CellMeat can strengthen its position as a leader in the cell-based meat market and continue to prioritise technology development”.

The company is known for developing a serum-free cell culture medium, helping to bring down the cost of production while removing any ethical issues associated with fetal bovine serum.

Last year, the company raised $8.1 million in a funding round, saying it would use the capital to double pilot production of its cultivated shrimp.

#CellMeat #SouthKorea

South Korea

Funding & Investments

Cell-based meat

Food

South Korea to establish first dedicated cultivated meat research centre

South Korea is launching its first cultivated meat research centre with ₩14.5B ($10M) public funding to strengthen its food tech leadership.

Simple Planet introduces serum-free cell culture medium

Simple Planet, a South Korean alternative protein lab, has developed an innovative serum-free cell culture medium using recycled probiotics.

Korean tri-party initiative launches to accelerate cultivated meat within the region

GFI APAC, KoreaBIO and the Bio-based Future Food Industry Committee have joined forces to accelerate cellular agriculture within the region.

Exclusive interview: Umami Bioworks CEO discusses new MoU with KCell Biosciences and WSG

Umami Bioworks has signed a MoU with South Korean biotech firm KCell Biosciences and bioprocess solutions provider WSG.